Abbas Ahmed, Rajabally Yusuf A
Department of Neurophysiology, Queen Elizabeth Hospital, University Hospital of Birmingham, Birmingham, United Kingdom.
Department of Neurology, Queen Elizabeth Hospital, University Hospital of Birmingham, Birmingham, United Kingdom.
Curr Drug Saf. 2019;14(1):3-13. doi: 10.2174/1574886313666181017121139.
Intravenous Immunoglobulin (IVIg) forms a cornerstone of effective treatment for acute and chronic inflammatory neuropathies, with a class I evidence base in Guillain-Barré Syndrome (GBS), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and multifocal motor neuropathy (MMN). It is generally considered to be a safe therapy however there are several recognised complications which are reviewed in this article.
Most adverse events are immediate and mild such as headache, fever and nausea although more serious immediate reactions such as anaphylaxis may rarely occur. Delayed complications are rare but may be serious, including thromboembolic events and acute kidney injury, and these and associated risk factors are also discussed. We emphasise the importance of safe IVIg administration and highlight practical measures to minimise complications of this therapy.
静脉注射免疫球蛋白（IVIg）是急性和慢性炎性神经病有效治疗的基石，在格林-巴利综合征（GBS）、慢性炎性脱髓鞘性多发性神经病（CIDP）和多灶性运动神经病（MMN）方面有I级证据基础。一般认为它是一种安全的治疗方法，然而本文将对几种已公认的并发症进行综述。
大多数不良事件是即刻且轻微的，如头痛、发热和恶心，尽管很少会发生如过敏反应等更严重的即刻反应。延迟性并发症很少见，但可能很严重，包括血栓栓塞事件和急性肾损伤，本文也将讨论这些并发症及相关风险因素。我们强调安全静脉注射免疫球蛋白的重要性，并强调将该治疗并发症降至最低的实际措施。
